Role Of HtrA And RseP, Stress Response Proteases, In Development And Persistence Of Chlamydia Trachomatis Infections
Funder
National Health and Medical Research Council
Funding Amount
$389,984.00
Summary
This project will research the most commonly reported bacterial sexually transmitted infection Chlamydia trachomatis. Bacterial proteins which could play a role in chronic infections of humans will be investigated. Proteins will be biologically examined to determine their role during disease. This may identify proteins which could be used for diagnostic and therapeutic tools to prevent chronic Chlamydia infection (which can result in infertility and other serious conditions).
Use Of Molecular Resistance Assays To Provide Alterative Oral Treatment Strategies For Gonorrhoea In Indigenous And Other High-risk Populations; A Randomised Cluster Trial
Funder
National Health and Medical Research Council
Funding Amount
$828,671.00
Summary
Gonorrhoea has now developed resistance to almost all antibiotics that have been used to treat it. In this study, we will investigate a new treatment approach that selects antibiotics on a patient-by-patient basis. We will use new molecular assays to first test if a gonorrhoea strain infecting a patient is susceptible to an antibiotic, and will then treat on the basis of this result. By doing so, we will optimize our use of antibiotics and improve treatment strategies for gonorrhea.
Population-level Epidemiological Trends In Hepatocellular Carcinoma In Queensland 1996 - 2010.
Funder
National Health and Medical Research Council
Funding Amount
$251,695.00
Summary
Incidence and mortality of hepatocellular carcinoma (HCC, the most common form of liver cancer) is increasing in Australia, driven by viral hepatitis infections. Disease burden is not defined in Queensland, particularly for Indigenous, migrant and regional and remote communities. Such factors may influence risk of viral hepatitis, access to treatment, and incidence and survival of HCC. Defining disease burdens will enable clinical programs targeted at groups most at risk in order to impact HCC t ....Incidence and mortality of hepatocellular carcinoma (HCC, the most common form of liver cancer) is increasing in Australia, driven by viral hepatitis infections. Disease burden is not defined in Queensland, particularly for Indigenous, migrant and regional and remote communities. Such factors may influence risk of viral hepatitis, access to treatment, and incidence and survival of HCC. Defining disease burdens will enable clinical programs targeted at groups most at risk in order to impact HCC trends.Read moreRead less
Evaluation Of Chlamydia Trachomatis Treatment Failure: A Cohort Study Of Women
Funder
National Health and Medical Research Council
Funding Amount
$761,844.00
Summary
Chlamydia is a very common sexually transmissible infection in Australia that can lead to infertility in women. About 4% of young adults have it. There is increasing concern by experts about the efficacy of the recommended chlamydia treatment. This is further supported by very high repeat infection rates following a previous positive chlamydia diagnosis. This study will measure whether chlamydia treatment failure is a problem and if so, this will change treatment guidelines worldwide.
Deadly Liver Mob: Engaging Aboriginal People In Viral Hepatitis, HIV And Sexual Health Services
Funder
National Health and Medical Research Council
Funding Amount
$848,441.00
Summary
Rates of blood-borne viruses and sexually transmissible infections are high among the Aboriginal and Torres Strait Islander population. A local initiative in western Sydney has trialed a new approach to engagement and care of Aboriginal people. We will implement this approach in services across NSW and evaluate its effectiveness as a sustainable and acceptable model for engaging Aboriginal people in care and develop an implementation plan for future roll-out to other services.
Eliminating Hepatitis C Transmission By Enhancing Hepatitis C Care And Treatment In Primary Health Care Settings.
Funder
National Health and Medical Research Council
Funding Amount
$1,221,831.00
Summary
In developed countries, people who inject drugs (PWID) are the group at greatest risk of hepatitis C (HCV) infection but few PWID receive HCV treatment. With the advent of highly effective non-interferon based treatments HCV elimination, although ambitious, is now being seriously considered globally. This partnership grant will explore the feasibility of eliminating HCV transmission by enhancing HCV care and treatment for PWID in primary health care settings.
Interventions To Improve Outcomes For Young Aboriginal And Torres Strait Islander People In Sexually Transmissible Infections Blood Borne Viruses And For People Using Methamphetamines
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
This ECF will enable research to be carried out in the domains of sexually transmissible infections (STI) and blood borne viruses (BBV) and specifically methamphetamine (MA) use in Aboriginal communities nationally. Specific research outcomes will be the establishment of an Aboriginal primary health care and behavioural surveillance network for STIs/BBVs in nationally dispersed clinical hubs (CRE), and an improved understanding of interventions to address MA in Aboriginal communities.
SCALE-C: Strategies For Hepatitis C Testing And Treatment In Aboriginal Communities That Lead To Elimination
Funder
National Health and Medical Research Council
Funding Amount
$2,175,170.00
Summary
Prevalence of hepatitis C infection within the Aboriginal population is among the highest of any identifiable population in Australia. Highly effective, direct-acting antiviral (DAA) therapy, and their listing on the PBS in 2016 has revolutionised HCV clinical management in Australia. The SCALE-C study will evaluate an established test and treat model to rapidly scale-up DAA within four Aboriginal communities to determine both impact on community prevalence and ongoing transmission.
Individualising Care For Patients With Chronic Hepatitis C: Predicting Side Effects And Treatment Response Using Genomic And Proteomic Approaches.
Funder
National Health and Medical Research Council
Funding Amount
$55,575.00
Summary
Patients undergoing treatment for hepatitis C must endure a treatment characterized by unpredictable treatment side effects and uncertainty about the likelihood of cure. This project will investigate genetic predictors of treatment related side-effects and protein markers to predict treatment response. Better definition of the risks and benefits of therapy, may facilitate patients and clinicians to make more informed decisions about treatment, thus individualising treatment and potentially impro ....Patients undergoing treatment for hepatitis C must endure a treatment characterized by unpredictable treatment side effects and uncertainty about the likelihood of cure. This project will investigate genetic predictors of treatment related side-effects and protein markers to predict treatment response. Better definition of the risks and benefits of therapy, may facilitate patients and clinicians to make more informed decisions about treatment, thus individualising treatment and potentially improving the safety and efficacy of therapy.Read moreRead less